ImmunOs Therapeutics raises CHF 71 million in B round
ImmunOs Therapeutics AG, a biotech company focused on a new class of HLA-based therapies for the treatment of cancer and autoimmune diseases today announced the...
Read more
As startups cannot appear in the TOP 100 for more than five years after incorporation, a growth jury was asked to select the TOP 25 scale-ups. These companies, aged five up to 10 years, show the greatest potential for further growth.
Entrepreneurship is not an exact science; startups do not automatically become scale-ups five years after their foundation. Engineering and biotech companies often take longer than ICT companies to reach this expansion phase. But all scale-ups have several things in common: The founders have proven that their innovations work, they have attracted customers, and they are now scaling their business models.

This article was first published in the TOP 100 Swiss Startup Magazine 2021.
ImmunOs Therapeutics AG, a biotech company focused on a new class of HLA-based therapies for the treatment of cancer and autoimmune diseases today announced the...
Read more
The shopping app Bring! and the leaflet app Profital are joining forces to shape the future of shopping. As of September 15, 2021, Swiss Post will increase its ...
Read moreThe fifth TOP 100 Investor Summit was the place to be for entrepreneurs and investors: Selected TOP 100 startups pitched their innovations to Swiss and internat...
Read moreDiscover the Who’s who of the Swiss startup ecosystem: Download the digital version of the TOP 100 Swiss Startup Magazine for free and learn more about the curr...
Read more
You have questions about Top100 or would like to exchange ideas with us? Feel free to contact me.
Jordi Montserrat Co-founder and managing partner jordi.montserrat@venturelab.swiss Jordi Montserrat on LinkedIn